Health & Environment
Serum Institute's HPV vaccine Cervavac receives WHO prequalification
The Hindu1h
THE BRIEF
1
Serum Institute of India's recombinant Quadrivalent Human Papillomavirus vaccine Cervavac received prequalification from the World Health Organization.
2
The inclusion on the WHO list allows United Nations agencies to procure the vaccine, which is indicated for girls and boys aged 9 through 26 years.
3
Developed in collaboration with the Department of Biotechnology and BIRAC, Cervavac targets HPV types 6, 11, 16, and 18 to prevent cervical, anal, and other associated cancers.